White House push for FDA approval of fruit-flavored vapes may have led to Makary's resignation
What this video covers
This CBS News segment, reported by correspondent Nikole Killion, covers the fallout from Dr. Marty Makary’s resignation as FDA Commissioner on May 12, 2026. According to reporting cited by CBS News, the immediate breaking point was a clash with the White House over FDA authorization of fruit-flavored vaping products — an area where Makary had reportedly resisted approval out of concern about youth uptake, while President Trump and senior officials favored a more permissive stance toward nicotine alternatives.
The reporting around the departure points to a multi-front squeeze. Per the Wall Street Journal, Makary’s exit followed a weekslong pressure campaign from anti-abortion activists who wanted faster restrictions on mifepristone, alongside the White House confrontation over flavored vapes. Reuters and other outlets reported that Trump had signed off on a plan to fire Makary, and Politico reported the resignation itself. The FDA had authorized mango and blueberry flavored products from Glas Inc., reportedly over Makary’s internal opposition.
In his own remarks, Trump struck a mild tone: “Marty’s a terrific guy, but he’s going to go on and he’s going to lead a good life,” while naming FDA Deputy Commissioner for Food Kyle Diamantas as acting head. HHS Secretary Robert F. Kennedy Jr. issued a statement thanking Makary, saying he had “taken on entrenched interests, challenged the status quo” and advanced the mission to “Make America Healthy Again.”
Key points
- CBS News reports that the Trump administration’s push for FDA approval of fruit-flavored vapes may have been the decisive factor in Makary’s resignation, which became public on May 12, 2026.
- Makary reportedly opposed authorizing flavored e-cigarettes because of youth-uptake and public-health concerns, while the White House favored expanding authorizations as adult-smoker alternatives.
- The FDA authorized Glas products in mango and blueberry flavors despite data showing fruit flavors are the most popular among youth, per subsequent congressional criticism from Rep. Krishnamoorthi.
- The Wall Street Journal reported Makary also faced a pressure campaign from anti-abortion activists over the speed of mifepristone restrictions.
- Trump named Kyle Diamantas, the FDA’s Deputy Commissioner for Human Foods, as acting commissioner; Kennedy said the search for a permanent commissioner would “move forward with urgency.”
- Kennedy’s farewell statement praised Makary’s “courage and friendship” and credited him with critical reforms — a public show of goodwill after a politically bruising exit.
- CBS notes internal FDA criticism of Makary’s management style — described by sources as micromanaging — and that a Senate Appropriations subcommittee hearing where he was expected to testify on the FDA budget was postponed the day of his resignation.